Overview

Phase I Cetuximab and Concurrent Radio-chemotherapy

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine
Phase:
Phase 1
Details
Lead Sponsor:
Maastricht Radiation Oncology
Collaborators:
Academisch Ziekenhuis Maastricht
Merck Sharp & Dohme Corp.
Treatments:
Cetuximab
Cisplatin
Vinorelbine